The firm, founded in 2009 and based in London, invests in early and mid-stage life sciences firms, with a focus on new drug discovery, med tech, enabling technologies, and vaccines industries. The team consists of 11 professionals with extensive scientific, medical, and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe, and the US. Advent Life Sciences has invested in companies that have discovered and developed fourteen approved medicines and products, partnering with management teams to bring innovation to patients and achieve superior financial returns.